NCT07510919Not yet recruiting
CGM in Acute Ischemic Stroke
Continuous Glucose Monitoring for Enhanced Management of Hyperglycemia in Persons With Type 2 Diabetes Undergoing Endovascular Therapy for Acute Ischemic Stroke: a Randomized Controlled Trial.
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
The goal of this randomized clinical trial is to evaluate whether continuous glucose monitoring (CGM) can be used to guide glucose management in patients with type 2 diabetes who are admitted with an acute ischemic stroke and undergo endovascular therapy. Hyperglycemia frequently occurs during hospitalization in stroke and is associated with worse neurological and clinical outcomes. In current clinical practice, glucose levels are monitored using intermittent point-of-care testing (POCT) with finger-prick measurements, which may miss clinically relevant glucose fluctuations. CGM provides continuous glucose measurements and may allow earlier detection of hyperglycemia and more timely glucose management. This study is designed as a non-inferiority randomized controlled trial comparing CGM-guided glucose management with standard POCT-guided glucose management. The primary objective is to determine whether CGM-guided glucose management is non-inferior to POCT-guided management in terms of percentage time spent in hyperglycemia (glucose \>10 mmol/L) during the first 72 hours of hospitalization. Researchers will compare CGM-guided glucose management to POCT-guided glucose management to evaluate whether CGM can be used as an alternative strategy to guide glucose control in hospitalized stroke patients. Participants will: * Be randomly assigned to either CGM-guided glucose management or standard POCT-guided glucose management * Have their glucose levels continuously monitored (blinded in the POCT-guided group) during hospitalization * Receive glucose management according to the assigned monitoring strategy, based on the hospital insulin protocol
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- First submitted
- 24 Mar 2026
- Start date
- Apr 2026
- Primary completion date
- May 2028
- Lead sponsor
- Isala
- Diseases
- Stroke, Type 2 diabetes
- NCT number
- NCT07510919
What you commit to
- Study type: Interventional
- Planned participants: 82
- From Apr 2026 to the primary completion date, May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications known to interfere with CGM accuracy, including:
- Systemic glucocorticoid therapy with a prednisone-equivalent dose \>5 mg/day
Other illness
- Extensive skin infections or dermatological conditions at the intended sensor site
- Clinically relevant pancreatic disease
Lab values
- Estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m²
Other
- Current pregnancy
- Medical situations known to interfere with CGM accuracy, including:
- Hypotension defined as a systolic blood pressure \<100 mmHg at 30 and 60 minutes after admission
- Dialysis treatment
- Acetaminophen \>4 g/day
- Dopamine
- High-dose vitamin C (ascorbic acid)
- Hydroxyurea / hydroxycarbamide
- Expected admission to an intensive care unit (ICU)
Who the study is looking for
- Age ≥18 years
- Acute ischemic stroke treated with endovascular therapy (EVT)
- Type 2 diabetes mellitus, defined as one of the following:
- documented diagnosis of type 2 diabetes mellitus
- use of glucose-lowering medication
- admission plasma glucose ≥11.1 mmol/L
- HbA1c ≥48 mmol/mol (≥6.5%)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.